Trade Tracker: Stephanie Link sells Nextera and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Fiscal Year: January - December
Intuitive Surgical, Inc. (ISRG), listed on the NASDAQ, has a market capitalization of $171.71B. As of Jun 07, 2025, the stock is trading at $557.08 per share, offering investors a clear view of its current market value. Intuitive Surgical, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 81.56, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Intuitive Surgical, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Intuitive Surgical, Inc. (ISRG) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Intuitive Surgical, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Intuitive Surgical, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Intuitive Surgical, Inc. is 114.35, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Intuitive Surgical, Inc. (ISRG) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Intuitive Surgical, Inc. (ISRG) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Intuitive Surgical, Inc. (ISRG) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Intuitive Surgical, Inc.. To access the full SS Score, consider upgrading your subscription.
Intuitive Surgical, Inc. is a significant player in the industry sector, with a market capitalization of $171.71B and a competitive P/E ratio of 81.56. Investors should compare these metrics with industry peers to gauge whether Intuitive Surgical, Inc. is outperforming or underperforming within its sector.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
James Demmert drops by the NYSE set with a couple of stocks to watch: Intuitive Surgical (ISRG) and BYD (BYDDY). He says both are plays that avoid a potential U.S. slowdown.
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investmen...
Intuitive Surgical's deep R&D investment and da Vinci 5 platform create a powerful innovation moat and embed the company further into surgical workflows. Recurring revenue from a growing installed bas...
Intuitive Surgical remains a dominant leader in robotic surgery with strong recurring revenues, high switching costs, and robust financial health. Business fundamentals are excellent, with resilient p...
Intuitive Surgical's share price has rebounded after a sharp drop, driven by strong Q1 2025 results and easing tariff concerns, with further upside expected. As the dominant leader in robotic surgery,...
President Dave Rosa promoted to CEO Current CEO Gary Guthart to become executive chair of Intuitive's board Current Board Chair Craig Barratt to become lead independent director
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasi...
SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that th...
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest buy of Intuitive Surgical
Intuitive Surgical's Q1 2025 earnings showed mixed results, with revenue and EPS beating expectations, but gross margins impacted by tariffs and a lower-margin product mix. Procedure volume growth was...
Intuitive Surgical Inc ISRG reported first-quarter 2025 revenue of $2.25 billion, beating analyst estimates of $2.19 billion.
Intuitive Surgical Inc ISRG reported better-than-expected first-quarter financial results Tuesday after the bell.
Surgical robots firm Intuitive Surgical said exports to and imports from China are subject to high tariffs. Shares are rising Wednesday on hopes the trade war will de-escalate.
Intuitive Surgical, Inc. (NASDAQ:ISRG) Q1 2025 Earnings Conference Call April 22, 2025 4:30 AM ET Company Participants Dan Connally - Head of IR Gary Guthart - CEO David Rosa - President Jamie Samath...
Intuitive Surgical raised concerns on Tuesday about the potential impact of tariffs on its annual results, despite exceeding Wall Street's first-quarter profit and revenue estimates.
SUNNYVALE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today...
Intuitive Surgical Inc ISRG will report its first-quarter earnings after the market closes on Tuesday. Wall Street expects earnings per share of $1.72 and revenue of $2.19 billion for the quarter.
Studies show robotic-assisted procedures enable increased access to minimally invasive care Studies show robotic-assisted procedures enable increased access to minimally invasive care
Intuitive's SureForm 45 stapler available for thoracic, colorectal, and urology procedures Intuitive's SureForm 45 stapler available for thoracic, colorectal, and urology procedures
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 2.93B | Analyst x4 | |
2026 | 3.52B | 19.87% | Analyst x6 |
2027 | 3.88B | 10.26% | Analyst x4 |
2028 | 3.83B | -1.33% | Analyst x1 |
2029 | 4.18B | 9.20% | Analyst x1 |
2030 | 4.32B | 3.29% | Est @3.3% |
2031 | 4.44B | 2.97% | Est @3.0% |
2032 | 4.57B | 2.74% | Est @2.7% |
2033 | 4.68B | 2.41% | Est @2.4% |
2034 | 4.78B | 2.30% | Est @2.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 749.60M | 1.00 | 749.60M |
2024A | 1.30B | 1.00 | 1.30B |
2025E | 2.93B | 1.10 | 2.66B |
2026E | 3.52B | 1.22 | 2.89B |
2027E | 3.88B | 1.34 | 2.89B |
2028E | 3.83B | 1.48 | 2.58B |
2029E | 4.18B | 1.63 | 2.56B |
2030E | 4.32B | 1.80 | 2.39B |
2031E | 4.44B | 1.99 | 2.23B |
2032E | 4.57B | 2.20 | 2.08B |
2033E | 4.68B | 2.42 | 1.93B |
2034E | 4.78B | 2.67 | 1.79B |
Terminal | 62.62B | 2.67 | 23.43B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.